title: Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway.
abstract: The co-transmitter neuropeptide Y (NPY), released during prolonged cardiac sympathetic nerve stimulation, can attenuate vagal-induced bradycardia. We tested the hypothesis that NPY reduces acetylcholine release, at similar concentrations to which it attenuates vagal bradycardia, via pre-synaptic Y2 receptors modulating a pathway that is dependent on protein kinase A (PKA) or protein kinase C (PKC). The Y2 receptor was immunofluorescently colocalized with choline acetyl-transferase containing neurons at the guinea pig sinoatrial node. The effect of NPY in the presence of various enzyme inhibitors was then tested on the heart rate response to vagal nerve stimulation in isolated guinea pig sinoatrial node/right vagal nerve preparations and also on (3)H-acetylcholine release from right atria during field stimulation. NPY reduced the heart rate response to vagal stimulation at 1, 3 and 5 Hz (significant at 100 nM and reaching a plateau at 250 nM NPY, p<0.05, n=6) but not to the stable analogue of acetylcholine, carbamylcholine (30, 60 or 90 nM, n=6) which produced similar degrees of bradycardia. The reduced vagal response was abolished by the Y2 receptor antagonist BIIE 0246 (1 microM, n=4). NPY also significantly attenuated the release of (3)H-acetylcholine during field stimulation (250 nM, n=6). The effect of NPY (250 nM) on vagal bradycardia was abolished by the PKC inhibitors calphostin C (0.1 microM, n=5) and chelerythrine chloride (25 microM, n=6) but not the PKA inhibitor H89 (0.5 microM, n=6). Conversely, the PKC activator Phorbol-12-myristate-13-acetate (0.5 microM, n=7) mimicked the effect of NPY and significantly reduced (3)H-acetylcholine release during field stimulation. These results show that NPY attenuates vagal bradycardia via a pre-synaptic decrease in acetylcholine release that appears to be mediated by a Y2 receptor pathway involving modulation of PKC.
authors.affiliation: Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, Parks Road, Oxford University OX1 3PT, UK.
authors.forename: Neil
authors.initials: N
authors.lastname: Herring
authors.forename: Michael N
authors.initials: MN
authors.lastname: Lokale
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Danson
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Heaton
authors.forename: David J
authors.initials: DJ
authors.lastname: Paterson
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D001919:Bradycardia / Q000188:drug therapy* / Q000503:physiopathology; D002217:Carbachol / Q000378:metabolism; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D005260:Female; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D007150:Immunohistochemistry; D007546:Isoquinolines / Q000494:pharmacology; D009478:Neuropeptide Y / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D017476:Receptors, Neuropeptide Y / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D012849:Sinoatrial Node / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D014630:Vagus Nerve / Q000187:drug effects / Q000503:physiopathology
chemical_list: D001552:Benzazepines; D007546:Isoquinolines; D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y; D013449:Sulfonamides; D002217:Carbachol; D001120:Arginine; D002795:Choline O-Acetyltransferase; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; C403256:BIIE 0246; D000109:Acetylcholine